Abstract
Purpose
The purpose of this study was to evaluate the appropriate 2-deoxy-2-[18F]fluoro-d-glucose–positron emission tomography (FDG-PET) determination in patients with inflammatory bowel disease (IBD) before and after clinical improvement to see if this determination correlates with clinical activity.
Procedures
We performed PET–computed tomography (PET/CT) on five patients before and after successful medical therapy in patients with moderately active IBD. Each patient had five bowel segments scored (0–3) for the appropriate FDG-PET determination.
Results
There were five patients [Crohn’s disease (CD) = 3, ulcerative colitis = 2] who were studied an average of 437 days (range, 77–807) after initial PET/CT scan. All patients showed significant improvement in physician global assessment scores (p = 0.004) and underwent repeat PET/CT. The total score of all segments was 32 pretreatment and 14 posttreatment (p < 0.01). Of 11 pretreatment active segments, nine (82%) segments either became inactive or displayed decreased activity, while two showed no change (p < 0.001).
Conclusion
Appropriate FDG-PET determination decreases with successful treatment of inflammation in active IBD and correlates with symptom improvement.

Similar content being viewed by others
References
Skehan SJ, Issenman R, Mernagh J, Nahmias C, Jacobson K (1999) 18F-fluorodeoxyglucose positron tomography in diagnosis of paediatric inflammatory bowel disease. Lancet 354:836–837 (PMID: 10485733)
Lemberg DA, Issenman RM, Cawdron R et al (2005) Positron emission tomography in the investigation of pediatric inflammatory bowel disease. Inflamm Bowel Dis 11:733–738 (PMID 16043988)
Neurath MF, Vehling D, Schunk K et al (2002) Noninvasive assessment of Crohn’s disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol 97:1978–1985 (PMID: 12190164)
Pio BS, Byrne FR, Aranda R et al (2003) Noninvasive quantification of bowel inflammation through positron emission tomography imaging of 2-deoxy-2-[18F]fluoro-d-glucose-labeled white blood cells. Mol Imaging Biol 5:271–277 (PMID: 14499142)
Löffler M, Weckesser M, Franzius C, Schober O, Zimmer KP (2006) High diagnostic value of 18F-FDG-PET in pediatric patients with chronic inflammatory bowel disease. Ann N Y Acad Sci 1072:379–385 (PMID: 17057218)
Meisner RS, Spier BJ, Einarsson S et al (2007) Pilot study using PET/CT as a novel, noninvasive assessment of disease activity in inflammatory bowel disease. Inflamm Bowel Dis 13:993–1000 (PMID: 17394243)
Louis E, Ancion G, Colard A, Spote V, Belaiche J, Hustinx R (2007) Noninvasive assessment of Crohn’s disease intestinal lesions with (18)F-FDG PET/CT. J Nucl Med 48:1053–1059 (PMID: 17574978)
Best WR, Becktel JM, Singleton JW, Kern F Jr (1976) Development of a Crohn’s disease activity index. National cooperative Crohn’s disease study. Gastroenterology 70:439–444
Sutherland L, Singleton J, Sessions J et al (1991) Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut 32:1071–1075
Harvey RF, Bradshaw JM (1980) A simple index of Crohn’s-disease activity. Lancet 1:514
Acknowledgment
This study was funded in part by an unrestricted grant from Procter & Gamble Pharmaceuticals.
Conflict of interest
None of the authors have conflicts of interest to disclose.
Author information
Authors and Affiliations
Corresponding author
Additional information
Manuscript Category and Significance
This is an original article describing the activity on PET/CT before and after treatment in patients with inflammatory bowel disease. This manuscript is important as it is the first to describe the appropriate FDG-PET determination after successful treatment in this subset of patients.
Rights and permissions
About this article
Cite this article
Spier, B.J., Perlman, S.B., Jaskowiak, C.J. et al. PET/CT in the Evaluation of Inflammatory Bowel Disease: Studies in Patients Before and After Treatment. Mol Imaging Biol 12, 85–88 (2010). https://doi.org/10.1007/s11307-009-0232-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-009-0232-1